F S&P 500
5,508.75 +17.75 (+0.32%) F Dow Jones
38,870.00 +11.00 (+0.03%) F Nasdaq
20,016.50 +97.25 (+0.49%) E-mini Russell 2000 Index Futur
2,051.20 +1.90 (+0.09%) Petróleo
81.59 +0.02 (+0.02%) Oro
2,353.20 +6.30 (+0.27%)
Eyenovia, Inc. (EYEN)
Antes de la apertura del mercado:
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
United States
833 393 6684
https://www.eyenovia.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 57
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Tsontcho Ianchulev M.D., M.P.H., MPH | Co-Founder & Executive Chairman | 167.5k | N/D | 1974 |
| Mr. Michael M. Rowe | CEO & Director | 775.47k | N/D | 1962 |
| Mr. John P. Gandolfo CPA | CFO & Secretary | 578.15k | N/D | 1961 |
| Mr. Bren Kern | COO & Corporate VP | 415.58k | N/D | 1981 |
| Alexander Lobo | Investor Contact | N/D | N/D | N/D |
Descripción
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Eyenovia, Inc. a partir del 1 de junio de 2024 es 6. Las puntuaciones principales son Auditoría: 4; Junta: 7; Derechos del accionista: 4; Compensación: 7.
